Extensive experience of disease control with gefitinib and the role of prognostic markers
Open Access
- 3 December 2003
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (S2) , S3-S8
- https://doi.org/10.1038/sj.bjc.6601476
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- O-243 Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use programLung Cancer, 2003
- P-620 Gefitinib (‘Iressa’, ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer (NSCLC)Lung Cancer, 2003
- P-613 The Israeli experience with gefitinib (‘Iressa’, ZD1839) as single agent treatment of advanced non-small-cell lung cancerLung Cancer, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?The Oncologist, 2002
- EGFR and cancer prognosisPublished by Elsevier ,2001
- Study of prognostic predictors for non-small cell lung cancerLung Cancer, 1999